Key Points {#s1}
==========

1.  **Question**: What neurological and musculoskeletal symptoms of COVID-19 are reported in the literature, and what is their prevalence?

2.  **Findings**: In this review, the reported neurological and musculoskeletal symptoms of COVID-19 are headache, dizziness, impaired consciousness, acute cerebrovascular disease, ataxia, seizure, impaired taste sensation, impaired smell sensation, impaired vision, myalgia, back pain, muscle weakness, skeletal muscle injury, arthralgia, and facial muscle pain. Their prevalence ranges from 1 to 35%.

3.  **Meaning**: Patients with COVID-19 may present with symptoms such as anosmia, seizure, ataxia, and muscle weakness, which are not among the commonly reported symptoms (fever, cough, and breathing difficulty), and these are still not understood. Therefore, recognizing such symptoms may help in early diagnosis and prevention of the disease. Similarly, it will help with planning the treatment of such symptoms and prevention of further complications in the long term.

Introduction {#s2}
============

COVID-19 is the disease associated with a novel coronavirus strain (SARS-CoV-2) belonging to the Nidovirales order, a case of which was first reported in 2019 from Wuhan city in China ([@B1]). The disease is said to be transmitted through droplets from human saliva, eyes, and nose ([@B2], [@B3]). When humans come into contact with these droplets, the virus can get into the body through the same routes and lodge in the lungs ([@B2]). In the lungs, it will bind with the angiotensin-converting enzymes 2 (ACE 2) in the alveolar cells and destroy them ([@B3], [@B4]). The alveolar cells play important roles in human respiration ([@B5]), and their damage can impair the process of respiration. Since the functioning of other systems and organs of the body requires normal functioning of the respiratory system, its impairment will, in turn, impair the functions of those systems and organs, leading to a state of disequilibrium. Consequently, symptoms of COVID-19 can be many and may also vary. So far, the most common notable early symptoms of the disease are believed to be cough, headache, and fever ([@B3]). However, recently, evidence is emerging on the effect of COVID-19 on the nervous and musculoskeletal systems ([@B6]--[@B8]).

The effects of COVID-19 on the nervous and musculoskeletal systems may manifest as anosmia, olfactory function impairment, myalgia, muscle weakness, and Guillian Barre Syndrome ([@B6]--[@B9]). However, there is still little evidence on these, as scientists are still struggling to understand the disease process, including the pathogenicity, virual replication, and epidemiology ([@B2], [@B7]). Ironically, in some patients, some of these symptoms may precede the commonest symptoms of COVID-19 ([@B10]). In addition, symptoms such as myalgia, muscle weakness, and headache may render the patients unable to carry out activities of daily living (ADL) such as walking. In humans, the ability to carry out ADL is associated with good quality of life ([@B11], [@B12]). Furthermore, symptoms such as muscle weakness can result in complications such as muscle atrophy and contracture in the long term. Therefore, identifying the neurological and musculoskeletal features of the disease would be beneficial and can provide further information with which to understand the diagnosis of COVID-19 and how to manage patients. The aim of this review is to summarize the evidence on the neurological and musculoskeletal symptoms of COVID-19.

Methods {#s3}
=======

Design and Protocol
-------------------

This is a systematic review and proportional meta-analysis that was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines ([@B13]). However, the protocol was not registered in any systematic review register because of the urgent need for literature on COVID-19 that can help curb the spread and impact of the disease.

Eligibility Criteria and Information Sources
--------------------------------------------

The inclusion criteria for this review were as follows: all studies with any study design that reported the neurological and musculoskeletal features in patients with COVID-19, studies published on or prior to April 17, 2020, and studies written in English. However, articles in the form of reviews, anecdotal description, and speculative considerations and editorials were excluded. Studies reporting exclusively on cases in children were also excluded. This is because the majority of the children infected with COVID-19 do not show any symptoms, and even in those who show symptoms, the symptoms tend to be limited to only mild fever and cough ([@B14]). Consequently, excluding children can enable us to generalize the findings to the adult population with COVID-19.

Four electronic databases, namely MEDLINE, EMBASE, Web of Science, and Google Scholar (first 100 hits), were searched from their date of establishment to April 17, 2020. The lists of references in the included studies were also screened for any relevant papers. The key search terms used were "coronavirus" and "signs and symptoms," modified in terms of the glossary of each database and combined using Boolean operators. The search was carried out by one of the reviewers (BK). [Appendix 1](#SM1){ref-type="supplementary-material"} demonstrates the search strategy applied in MEDLINE.

Selection of Eligible Studies and Extraction of Data
----------------------------------------------------

EndNote and Rayyan were used to remove any duplicates and select eligible studies from the database findings and other sources (lists of references in included studies). Two independent reviewers (AA and SAC) who have experience in conducting systematic reviews selected the eligible studies using Rayyan software ([@B15]). Any disagreement between reviewers was resolved by consensus or by a third reviewer (BK).

A standardized form was used to extract the relevant data by three reviewers (AA, NUM, and MAA). The data extracted from each study were the study details (study title, first author, year, setting/country, study design), participant details (sex, age, overall sample size, number of patients in critical and non-critical conditions, comorbidities, diagnostic criteria used for the disease (COVID-19), and information about the treatments received), and neurological features, such as headache, dizziness, impaired consciousness, acute cerebrovascular disease, ataxia, seizure, taste impairment, smell impairment, vision impairment, neuropathic pain, and musculoskeletal features such as myalgia and back pain. In addition, the number of patients presenting with a particular symptom was also extracted.

Assessment of the Methodological Quality of the Included Studies
----------------------------------------------------------------

A modified McMaster Critical Review Form for quantitative studies was used to critically assess the methodological quality of the included studies ([@B16]). This form is a comprehensive quality tool and can be used to assess all types of quantitative studies. It consists of 17 items with four answer options for each item (yes, no, not addressed and not applicable) to assess seven main components, including study purpose, literature review, study design, sample size, outcomes, interventions, results, and conclusions. Each item receives a score of zero when the answer to a particular item is no or not addressed and a score of one when the answer to a particular item is yes. However, when an item is not applicable to a particular study design, no score is awarded; NA is used to designate this. The scores from the tool are classified as poor, fair, good, or excellent, representing 1/4 or less, ≤2/4, ≥2/4 but ≤3/4, and \>3/4 to 4/4 of the total score, respectively. The level of evidence was also determined using the National Health and Medical Research Council\'s (NHMRC) evidence hierarchy ([@B17]). Two independent reviewers performed the quality assessment (ABH and AA). Any disagreements between the first and the second reviewers were resolved through discussion to reach consensus and/or by a third reviewer (NUA). See the McMaster Critical Review Form in [Appendix 2](#SM1){ref-type="supplementary-material"}.

Data Analysis
-------------

Qualitative and quantitative data (descriptive and proportional meta-analysis) analyses were performed. The descriptive analysis was performed and represented in the form of summary tables. The proportional meta-analysis was performed using StataSE 16 for the quantitative data if there were at least two studies that reported the proportion of the same clinical symptom. A random-effect model due to the heterogeneity and Freeman-Tukey double arc-sine transformation were used to stabilize the variance of specific prevalence rates to minimize the impact of studies with extremely small or extremely large prevalence estimates on overall estimates ([@B18]). The *I*^2^ index was also calculated to assess the level of heterogeneity, which can be classified into four categories: might not be important (0--40%), may represent moderate heterogeneity (30--60%), may represent substantial heterogeneity (50--90%), and considerable heterogeneity (75--100%). Publication bias was assessed using a funnel plot and Egger\'s test ([@B19]).

Results {#s4}
=======

A total of 1,301 published articles were identified from the electronic databases (*n* = 1,298) and other sources (*n* = 3). After the removal of duplicate studies (*n* = 396), 905 studies were eligible for an initial screening based on titles and abstracts. Following the initial screening, 771 records were removed, and the full-texts of 134 articles were screened against the defined eligibility criteria. After the full-text screening, 60 articles ([@B4], [@B9], [@B10], [@B20]--[@B76]) met the inclusion criteria and were used for qualitative synthesis. For the quantitative synthesis, only 51 articles ([@B4], [@B9], [@B20]--[@B29], [@B31], [@B32], [@B34]--[@B36], [@B38], [@B41]--[@B43], [@B45]--[@B70], [@B72], [@B73], [@B75], [@B76]) were used. [Figure 1](#F1){ref-type="fig"} shows the PRISMA flowchart.

![Study PRISMA Flow chart.](fneur-11-00687-g0001){#F1}

The total number of participants in the included studies was 11,069, of which 5,168 were male. The median or mean age of the participants ranges from 24 to 95 years. Based on the studies reporting the situations of the patients, there were 2,377 and 4,882 participants in critical and non-critical conditions, respectively. The most common neurological manifestation was headache (35 studies; 58.33%) ([@B4], [@B23], [@B25]--[@B28], [@B30], [@B31], [@B34]--[@B36], [@B41]--[@B48], [@B50], [@B52], [@B53], [@B56]--[@B63], [@B67]--[@B70], [@B72]), followed by dizziness (6 studies; 10%) ([@B29], [@B34], [@B45], [@B53], [@B54], [@B56]), impaired smell sensation (5 studies; 8.33%) ([@B33], [@B34], [@B36], [@B43], [@B55]), impaired taste sensation (4 studies; 6.67%) ([@B34], [@B36], [@B43], [@B53]), acute cerebrovascular disease (2 studies; 3.33%) ([@B34], [@B57]), ataxia (2 studies; 3.33%) ([@B9], [@B34]), seizure (2 studies; 3.33%) ([@B30], [@B34]), impaired consciousness (1 study; 1.6%) ([@B30]), and impaired vision (1 study; 1.6%) ([@B34]). However, one study ([@B20]) reported non-specified neurological symptoms. The most common musculoskeletal manifestation was myalgia (48 studies; 80%) ([@B4], [@B20]--[@B23], [@B25]--[@B29], [@B31], [@B32], [@B36]--[@B38], [@B41]--[@B44], [@B46]--[@B71], [@B73], [@B75], [@B76]), followed by back pain (4 studies; 6.67%) ([@B25], [@B40], [@B62], [@B63]), muscle weakness (1 study; 1.67%) ([@B9]), skeletal muscle injury (1 study; 1.67%) ([@B34]), arthralgia (1 study; 1.67%) ([@B36]), and facial muscle pain (1 study; 1.67%) ([@B36]).

In terms of the study design, four of the studies were case series ([@B22], [@B34], [@B56], [@B76]), 10 studies ([@B9], [@B10], [@B27], [@B30], [@B33], [@B39], [@B40], [@B44], [@B71], [@B74]) were case reports, and 46 studies ([@B4], [@B20]--[@B26], [@B28]--[@B30], [@B33], [@B39], [@B40], [@B44], [@B71], [@B74]) were either cohort or cross-sectional studies. All the studies were published in 2020. The settings/countries of the included studies were as follows: five studies ([@B40], [@B43], [@B74]--[@B76]) were carried out in the United States, and one each was carried out in the United Kingdom ([@B33]), Spain ([@B38]), Italy ([@B9]), South Korea ([@B63]), France ([@B39]), and Japan ([@B30]); one study ([@B36]) is a multicenter study carried out in Europe (Belgium, France, Italy, and Spain). The rest of the studies ([@B4], [@B10], [@B20]--[@B29], [@B31]--[@B35], [@B37], [@B41]--[@B62], [@B64]--[@B68], [@B70]--[@B73]) were carried out in China. In most of the studies, the Chinese national CDC recommended protocol, World Health Organization (WHO) interim guidance, and real-time polymerase chain reaction (RT-PCR) were used to confirm the diagnosis of the disease. There were many comorbidities in the included studies such as hypertension, diabetes, cardiac or cerebrovascular disease, malignancy, chronic kidney disease, pituitary adenoma, chronic obstructive pulmonary disease, chronic renal failure, and cancer. Others are pregnancy, hepatitis B infection, allergic rhinitis, immune-suppression, history of head trauma, and neurological disease. [Table 1](#T1){ref-type="table"} shows the details and characteristics of the included studies.

###### 

Details and characteristics of the included studies.

  **References**              **Country**           **Study design**                        **Number of patients (overall)**   **Number of patients (critical)**   **Number of patients (non-critical)**   **Number of male patients**   **Mean/median age (years)**   **Headache**   **Dizziness**   **Impaired consciousness**   **Acute cerebrovascular disease**   **Ataxia**   **Seizure**   **Taste impairment**   **Smell impairment**   **Vision impairment**   **Nerve pain**   **Myalgia**   **Back pain**   **Muscle weakness**   **Skeletal muscle injury**   **Arthralgia**   **Facial muscle pain**   **Illness onset**   **Neurological symptoms**
  --------------------------- --------------------- --------------------------------------- ---------------------------------- ----------------------------------- --------------------------------------- ----------------------------- ----------------------------- -------------- --------------- ---------------------------- ----------------------------------- ------------ ------------- ---------------------- ---------------------- ----------------------- ---------------- ------------- --------------- --------------------- ---------------------------- ---------------- ------------------------ ------------------- ---------------------------
  Feng et al. ([@B20])        China                 Cohort                                  476                                124                                 352                                     271                           53 (40--60)                   NA             NA              NA                           AA                                  NA           NA            NA                     NA                     NA                      NA               55            NA              NA                    NA                                                                     4 (2--7)            47/440 (10.7)
  Lei et al. ([@B21])         China                 Cross-sectional                         199                                24                                  53                                      77                            49.35                         NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               18            NA              NA                    NA                                                                     NA                  NA
  Zhang et al. ([@B22])       China                 Cross-sectional                         120                                30                                  90                                      43                            45.4                          NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               57            NA              NA                    NA                                                                     NA                  NA
  Han et al. ([@B23])         China                 Cross-sectional                         108                                NA                                  NA                                      38                            45                            14             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               12            NA              NA                    NA                                                                     1-3(1)              NA
  Qian et al. ([@B25])        China                 Cross-sectional                         91                                 NA                                  NA                                      37                            50 (IQR, 36.5 to 57.0)        7              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               7             9               NA                    NA                                                                     NA                  NA
  Chen et al. ([@B26])        China                 Cross-sectional                         99                                 NA                                  NA                                      67                            55·5 (13·1)                   8              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               11            NA              NA                    NA                                                                     NA                  NA
  Jin et al. ([@B27])         China                 Cross-sectional                         651                                NA                                  NA                                      331                           45.62                         67             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               71            NA              NA                    NA                                                                     NA                  NA
  Zhang et al. ([@B28])       China                 Cross-sectional                         645                                NA                                  NA                                      328                           40.78                         67             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               71            NA              NA                    NA                                                                     NA                  NA
  Lon et al. ([@B29])         China                 Cross-sectional                         10                                 4                                   6                                       3                             54 (27--64)                   NA             2               NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               3             NA              NA                    NA                                                                     NA                  NA
  Moriguchi et al. ([@B30])   Japan                 Case report                             1                                  NA                                  NA                                      1                             24                            1              NA              1                            NA                                  NA           1             NA                     NA                     NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Du et al. ([@B31])          China                 Cross-sectional                         109                                51                                  58                                      74                            70.7                          8              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               19            NA              NA                    NA                           NA               NA                       NA                  NA
  Zhang et al. ([@B32])       China                 Case series                             5                                  NA                                  NA                                      4                             45                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               3             NA              NA                    NA                           NA               NA                       NA                  NA
  Gane et al. ([@B33])        UK                    Case report                             1                                  NA                                  NA                                      1                             48                            NA             NA              NA                           NA                                  NA           NA            NA                     1                                              NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Mao et al. ([@B34])         China                 Case series                             214                                58.2                                58.2                                    87                            131                           28             36              16                           6                                   1            1             12                     11                     3                       NA               NA            NA              NA                    23                           NA               NA                       NA                  NA
  Han et al. ([@B35])         China                 Cross-sectional                         17                                 NA                                  NA                                      6                             40                            4              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Lechien et al. ([@B36])     Multi-center/Europe   Cross-sectional                         417                                NA                                  NA                                      154                           36.9 ± 11.4                   188            NA              NA                           NA                                  NA           NA            342                    357                    NA                      NA               242           NA              NA                    NA                           133              Present                  NA                  NA
  Jin and Tong ([@B37])       China                 Case report                             1                                  NA                                  1                                       1                             60                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               Present       NA              NA                    NA                           NA               NA                       NA                  NA
  Barrasa et al. ([@B38])     Spain                 Cross-sectional                         48                                 48                                  0                                       27                            63.2 (12)                     NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               2             NA              NA                    NA                           NA               NA                       NA                  NA
  Eliezer et al. ([@B39])     France                Case report                             1                                  0                                   1                                       0                             40                            NA             NA              NA                           NA                                  NA           NA            NA                     1                      NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Zhao et al. ([@B10])        China                 Case report                             1                                  0                                   1                                       0                             61                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Kim et al. ([@B40])         USA                   Case report                             1                                  NA                                  1                                       1                             42                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               NA            1               NA                    NA                           NA               NA                       NA                  NA
  Lian et al. ([@B41])        China                 Restrospective study                    788                                78                                  710                                     407                           54.72                         75             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               91            NA              NA                    NA                           NA               NA                       NA                  NA
  Shi et al. ([@B42])         China                 Cohort study                            416                                NA                                  NA                                      205                           64 (21--95)                   9              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               19            NA              NA                    NA                           AN               NA                       NA                  NA
  Yan et al. ([@B43])         USA                   Cross sectional                         59                                 NA                                  NA                                      29                            18--79                        25             NA              NA                           NA                                  NA           NA            12                     13                     NA                                       20            NA              NA                    NA                           NA               NA                       NA                  NA
  Yang et al. ([@B44])        China                 Case report                             4                                  NA                                  NA                                      1                             NA                            2              NA              NA                           NA                                  NA           NA            NA                     NA                                             NA               1             NA              NA                    NA                           NA               NA                       NA                  NA
  Mi et al. ([@B45])          China                 Restrospective study                    10                                 NA                                  NA                                      2                             34--87                        1              3               NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Wu et al. ([@B46])          China                 Restrospective study                    80                                 NA                                  NA                                      42                            44 ([@B11])                   8              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               13            NA              NA                    NA                           NA               NA                       NA                  NA
  Lei et al. ([@B47])         China                 Restrospective study                    14                                 NA                                  NA                                      8                             12--83                        2              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               1             NA              NA                    NA                           NA               NA                       NA                  NA
  Xu et al. ([@B48])          China                 Restrospective study                    50                                 37                                  13                                      29                            43.9 ± 16.8 (3--85)           5              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               8             NA              NA                    NA                           NA               NA                       NA                  NA
  LI et al. ([@B49])          China                 Restrospective study                    25                                 16                                  9                                       12                            48                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               17            NA              NA                    NA                           NA               NA                       NA                  NA
  Yang et al. ([@B50])        China                 Retrospective multi-center cohort       149                                NA                                  NA                                      81                            45.11 ± 13.35                 13             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               5             NA              NA                    NA                           NA               NA                       NA                  NA
  Chen et al. ([@B51])        China                 Retrospective study                     9                                  NA                                  NA                                      0                             26-40                         NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               3             NA              NA                    NA                           NA               NA                       NA                  NA
  Liang et al. ([@B52])       China                 Retrospective study                     1,590                              1187                                403                                     904                           48.9 ± 16.3                   205                            20                           NA                                  NA           NA            NA                     NA                     NA                      NA               234           NA              NA                    NA                           NA               NA                       NA                  NA
  Chen et al. ([@B53])        China                 Restrospective study                    203                                96                                  107                                     108                           54 (20--91)                   10             4               NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               54            NA              NA                    NA                           NA               NA                       NA                  NA
  Hu et al. ([@B54])          China                 Restrospective study                    24                                 NA                                  NA                                      8                             5-95                                         1               NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               1             NA              NA                    NA                           NA               NA                       NA                  NA
  Chu et al. ([@B55])         China                 Restrospective study                    54                                 11                                  43                                      36                            39 (26--73)                                  NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               3             NA              NA                    NA                           NA               NA                       NA                  NA
  Wang et al. ([@B56])        China                 Case series                             138                                102                                 36                                      75                            56 (42--68)                   9              13              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               48            NA              NA                    NA                           NA               NA                       NA                  NA
  Zheng et al. ([@B57])       China                 Retrospective analysis                  161                                30                                  131                                     80                            45                            12             NA              NA                           4                                   NA           NA            NA                     NA                     NA                      NA               18            NA              NA                    NA                           NA               NA                       NA                  NA
  Guan et al. ([@B58])        China                 Cohort                                  1,099                              173                                 926                                     64                            47                            150            NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               164           NA              NA                    NA                           NA               NA                       4(2--7)             NA
  Wu et al. ([@B59])          China                 Retrospective multicenter descriptive   80                                 3                                   77                                      39                            46.1                          13             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               18            NA              NA                    NA                           NA               NA                       NA                  NA
  Wang et al. ([@B60])        China                 Descriptive                             1,012                              0                                   1,012                                   524                           50                            152            NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               170           NA              NA                    NA                           NA               NA                       NA                  NA
  Lui et al. ([@B61])         China                 Retrospective                           137                                NA                                  NA                                      61                            57                            13             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               44            NA              NA                    NA                           NA               NA                       NA                  NA
  Ye et al. ([@B24])          China                 Cohort                                  55                                 NA                                  NA                                      19                            37                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Yang et al. ([@B62])        China                 Retrospective                           52                                 52                                  0                                       35                            59·7                          3              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               6             1               NA                    NA                           NA               NA                       NA                  NA
  Kim et al. ([@B63])         South Korea           Cohort study                            28                                 0                                   28                                      15                            42.6                          7              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               7             7               NA                    NA                           NA               NA                       NA                  NA
  Cheng et al. ([@B64])       China                 Cohort                                  11                                 NA                                  NA                                      8                             50.36                         NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               3             NA              NA                    NA                           NA               NA                       NA                  NA
  Xu et al. ([@B65])          China                 Cross sectional                         51                                 NA                                  NA                                      25                            42                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               8             NA              NA                    NA                           NA               NA                       NA                  NA
  Cao et al. ([@B66])         China                 Cross sectional                         102                                NA                                  NA                                      53                            45                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               35            NA              NA                    NA                           NA               NA                       NA                  NA
  Wan et al. ([@B67])         China                 Cohort                                  135                                56                                  40                                      95                            49                            34             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               44            NA              NA                    NA                           NA               NA                       NA                  NA
  Wang et al. ([@B68])        China                 Cross sectional                         69                                 14                                  55                                      32                            42                            10             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               21            NA              NA                    NA                           NA               NA                       NA                  NA
  Du et al. ([@B69])          China                 Cross sectional                         85                                 85                                  0                                       62                            65.8                          4                              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               14            NA              NA                    NA                           NA               NA                       NA                  NA
  Huang et al. ([@B4])        China                 Cross sectional                         41                                 13                                  28                                      30                            49·0                          3              NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               18            NA              NA                    NA                           NA               NA                       NA                  NA
  Xu et al. ([@B70])          China                 Cross sectional                         62                                 NA                                  NA                                      35                            41                            21             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               32            NA              NA                    NA                           NA               NA                       NA                  NA
  Dongyan et al. ([@B71])     China                 Case report                             1                                  0                                   1                                       1                             35                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               1             NA              NA                    NA                           NA               NA                       NA                  NA
  Wang et al. ([@B72])        China                 Cross sectional                         339                                NA                                  NA                                      166                           69                            12             NA              NA                           NA                                  NA           NA            NA                     AN                     NA                      NA               16            NA              NA                    NA                           NA               NA                       NA                  NA
  Cai et al. ([@B73])         China                 Cross sectional                         298                                58                                  240                                     145                           47.5                          NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Tape et al. ([@B74])        USA                   Case report                             1                                  NA                                  NA                                      0                             79                            NA             NA              1                            NA                                  NA           NA            NA                     NA                     NA                      NA               1             NA              NA                    NA                           NA               NA                       NA                  NA
  Bhatraju et al. ([@B75])    USA                   Cross sectional                         24                                 24                                  0                                       15                            64                            NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               NA            NA              NA                    NA                           NA               NA                       NA                  NA
  Goyal et al. ([@B76])       USA                   Case series                             393                                NA                                  NA                                      238                           62.2                          NA             NA              NA                           NA                                  NA           NA            NA                     NA                     NA                      NA               107           NA              NA                    NA                           NA               NA                       NA                  NA
  Toscano et al. ([@B9])      Italy                 Case report                             5                                  3                                   2                                       NA                            NA                            NA             NA              NA                           NA                                  1            NA            NA                     NA                     NA                      NA               NA            NA              4                     NA                           NA               NA                       NA                  NA

The methodological quality of the included studies was variable. Fifty-eight studies ([@B4], [@B9], [@B10], [@B20]--[@B23], [@B25]--[@B39], [@B41]--[@B76]) have excellent methodological quality, one study ([@B40]) has good methodological quality, and one study ([@B24]) has fair methodological quality. In terms of the level of the evidence (based on NHMRC evidence hierarchy), one study is a level II study, three studies are level III-I studies, 35 studies are level III-2 studies, seven studies are level III-3 studies, and 14 studies are level IV studies. [Table 2](#T2){ref-type="table"} shows the methodological quality and the level of evidence of the included studies.

###### 

Levels of evidence and methodological quality of the included studies.

  **References**              **Design**                               **Level of evidence**   **1**   **2**   **3**   **4**   **5**   **6**   **7**   **8**   **9**   **10**   **11**   **12**   **13**   **14**   **15**   **16**   **17**   **Total score**
  --------------------------- ---------------------------------------- ----------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------- -------- -------- -------- -------- -------- -------- -------- -----------------
  Feng et al. ([@B20])        Cohort                                   III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Lei et al. ([@B21])         Cross-sectional                          III-2                   Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      No       Yes      9/11
  Zhang et al. ([@B22])       Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Han et al. ([@B23])         Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Qian et al. ([@B25])        Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Chen et al. ([@B26])        Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       No       Yes      NA       Yes      7/9
  Jin et al. ([@B27])         Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       No       Yes      NA       Yes      7/9
  Zhang et al. ([@B28])       Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Lon et al. ([@B29])         Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      No       Yes      NA       Yes      8/9
  Moriguchi et al. ([@B30])   Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Du et al. ([@B31])          Cross-sectional                          III-3                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Zhang et al. ([@B32])       Case series                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Gane et al. ([@B33])        Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Mao et al. ([@B34])         Case series                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Han et al. ([@B35])         Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Lechien et al. ([@B36])     Cross-sectional                          III-2                   Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      No       Yes      9/11
  Jin and Tong ([@B37])       Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Barrasa et al. ([@B38])     Cross-sectional                          II                      Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      No       Yes      9/11
  Eliezer et al. ([@B39])     Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      No       NA       Yes      7/9
  Zhao et al. ([@B10])        Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Kim et al. ([@B40])         Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      NA      NA      NA       No       NA       No       No       Yes      No       Yes      5/9
  Lian et al. ([@B41])        Retrospective study                      III-3                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Shi et al. ([@B42])         Cohort                                   III-3                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Yan et al. ([@B43])         Cross sectional                          III-1                   Yes     Yes     Yes     No      NA      NA      NA      No      No      NA       Yes      NA       Yes      Yes      Yes      No       Yes      8/12
  Yang et al. ([@B44])        Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       Yes      NA       No       NA       Yes      NA       Yes      8/9
  Mi et al. ([@B45])          Retrospective cohort study               III-3                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       NA       Yes      Yes      Yes      8/9
  Wu et al. ([@B46])          Retrospective study                      III-3                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Lei et al. ([@B47])         Retrospective study                      III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Xu et al. ([@B48])          Retrospective study                      III-1                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Li et al. ([@B49])          Retrospective study                      III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Yang et al. ([@B50])        Retrospective cohort study               III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Chen et al. ([@B51])        Retrospective study                      III-3                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Liang et al. ([@B52])       Retrospective cohort study               III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Chen et al. ([@B53])        Retrospective study                      III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       NA       Yes      Yes      NA       Yes      9/9
  Hu et al. ([@B54])          Retrospective study                      III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Chu et al. ([@B55])         Retrospective study                      III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Wang et al. ([@B56])        Case series                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Zheng et al. ([@B57])       Retrospective study                      III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Guan et al. ([@B58])        Cohort                                   III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Wu et al. ([@B59])          Retrospective multi-center descriptive   III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Wang et al. ([@B60])        Descriptive                              III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Wang et al. ([@B61])        Retrospective study                      III-2                   Yes     No      Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      7/9
  Ye et al. ([@B24])          Cohort                                   III-2                   Yes     No      No      NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       No       Yes      NA       Yes      5/9
  Yang et al. ([@B62])        Retrospective study                      III-3                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Kim et al. ([@B63])         Cohort study                             III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       No       Yes      NA       Yes      7/9
  Cheng et al. ([@B64])       Cohort                                   III-1                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Xu et al. ([@B65])          Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Cao et al. ([@B66])         Cohort                                   III-2                   Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/10
  Wan et al. ([@B67])         Cohort                                   III-2                   Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/10
  Wang et al. ([@B68])        Cross-sectional                          III-2                   Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      No       Yes      9/11
  Du et al. ([@B69])          Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/9
  Huang et al. ([@B4])        Cross-sectional                          III-2                   Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       Yes      Yes      Yes      NA       Yes      9/10
  Xu et al. ([@B70])          Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Dongyan et al. ([@B71])     Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Wang et al. ([@B72])        Cross-sectional                          III-2                   Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Cai et al. ([@B73])         Cross-sectional                          III-2                   Yes     Yes     Yes     No      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      No       Yes      8/11
  Tape et al. ([@B74])        Case report                              IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Bhatraju et al. ([@B75])    Cross sectional                          IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Goyal et al. ([@B76])       Retrospective case series                IV                      Yes     Yes     Yes     NA      NA      NA      NA      Yes     Yes     NA       NA       NA       No       Yes      Yes      NA       Yes      8/9
  Toscano et al. ([@B9])      Case report                              IV                      Yes     No      Yes     NA      NA      NA      NA      Yes     Yes     NA       Yes      NA       No       NA       Yes      NA       Yes      7/9

The proportional meta-analyses revealed that the prevalence of common neurological and musculoskeletal manifestations was 35% for smell impairment (95% CI 0--94%; *I*^2^ 99.63%), 33% for taste impairment (95% CI 0--91%; *I*^2^ 99. 58%), 19% for myalgia (95% CI 16--23; *I*^2^ 95%), 12% for headache (95% CI 9--15; *I*^2^ 93.12%), 10% for back pain (95% CI 1--23%; *I*^2^ 80.20%), 10% for dizziness (95% CI 3--19%; *I*^2^ 86.74%), 3% for acute cerebrovascular disease (95% CI 1--5%; *I*^2^ 0%), and 2% for impaired consciousness (95% CI 1--2%; *I*^2^ 0%). [Figure 2](#F2){ref-type="fig"} shows the forest plots for the prevalence of acute cerebrovascular disease, impaired consciousness, back pain, dizziness, headache, myalgia, smell impairment, and taste impairment.

![Forest plots for the prevalence of the Neurological and Musculoskeletal Features of Covid-19.](fneur-11-00687-g0002){#F2}

The visual symmetry of the funnel plots suggests that there was no publication bias for headache, dizziness, and myalgia. These results were also confirmed by Egger\'s test, which revealed statistically insignificant *p*-values. See [Figure 3](#F3){ref-type="fig"} for the funnel plots.

![Funnel plots for publication bias for headache, dizziness and myalgia.](fneur-11-00687-g0003){#F3}

Discussion {#s5}
==========

The results showed that the prevalence of neurological and musculoskeletal manifestations of COVID-19 was 35% for smell impairment, 33% for taste impairment, 19% for myalgia, 12% for headache, 10% for back pain, 3% for acute cerebrovascular disease, and 2% for impaired consciousness. In addition, the majority of the studies have excellent methodological quality, which is an indication of the validity and reliability of the studies ([@B77]). Thus, it is important that clinicians consider these symptoms during diagnosis of the disease and management of the patients to help prevent the spread of the disease and the development of any complications. For instance, acute cerebrovascular disease can manifest as symptoms such as stroke, seizure, and headache, which can result in long-term disability that may require rehabilitation for a very long time ([@B78]--[@B80]). Similarly, symptoms such as muscle weakness, myalgia, vision impairment, and arthralgia can interfere with patients\' ability to carry out activities of daily living (ADL). When people are able to carry out ADL, they tend to have better quality of life ([@B11], [@B12]).

In addition, two of the most important factors about COVID-19 are that it is highly contagious and most of the people infected may not present with any notable symptoms such as fever and cough ([@B56]). This means that the presence of some previously unnoticed symptoms such as muscle weakness, visual impairment, and arthralgia may not raise any suspicion of the disease. As such, many unnoticed cases could infect many others and increase the spread of the disease. Delineating the whole spectrum of the symptoms patients with COVID-19 present with can help with prompt diagnosis, isolation, and treatment of cases.

One important finding in this study is that there are more neurological symptoms than musculoskeletal symptoms in patients with COVID-19. This may not be surprising, as the virus is believed to be neurotrophic, and the patients may therefore present with neurological symptoms or complications, especially in the long term ([@B81], [@B82]). Similarly, it is also possible that the patients will present with more musculoskeletal symptoms and complications in the long-term due to prolonged immobilization ([@B83], [@B84]). It is also worth noting that many of the symptoms in patients with COVID-19 are non-specific and cannot be highlighted as support for the early diagnosis of the disease. For instance, symptoms such as headache and impaired consciousness may be related to the respiratory failure. However, based on the reviewed studies reporting on the situations of the patients, the majority of the participants were not in critical condition. Therefore, it cannot be said with certainty that these non-specific symptoms are the result of respiratory failure.

Nevertheless, several factors may be the likely causes of the neurological and musculoskeletal features of COVID-19. Firstly, the virus may gain access to, for example, the central nervous system via the bloodstream and infect endothelial cells or leukocytes or through retrograde neuronal routes by infecting the peripheral nerves ([@B85]). Secondly, the virus causes pneumonia, which may result in systemic hypoxia, which will eventually damage the brain and other nerve cells ([@B86]). The processes through which the damage occurs include peripheral vasodilatation, hypercabia, hypoxia, and anaerobic metabolism, which ultimately result in neuronal swelling and brain edema ([@B87]). Neural swelling and brain edema can raise intracranial pressure and result in impaired consciousness and seizure or can irritate the trigeminal nerve and cause headache ([@B88], [@B89]). In addition, cytokine storms characterized by increased levels of inflammatory cytokines and activities of T lymphocytes, macrophages, and endothelial cells can also cause neuronal damage. In particular, the release of interleukin-6 causes vascular leakage and activation of complement and coagulation cascades ([@B90]). Consequently, it was noted that patients with the severe disease (COVID-19) tend to have higher levels of D-dimer, which is a marker of a hypercoagulable state and endogenous fibrinolysis ([@B34], [@B91]). These may be the factors that cause acute cerebrovascular disease in patients with COVID-19. Similarly, the elevated level of serum interleukin-6 during cytokine storms could be the cause of myalgia ([@B92]). The cytokine storm may also be the cause of the arthralgia presented by the patients. This is because interleukin-6 is a pro-inflammatory substance ([@B93]), and viral infections are also known to cause arthralgia ([@B94]). Thus, it is possible that arthralgia, which is joint pain, is associated with myalgia in patients with COVID-19.

Although we excluded studies in children because they generally present only with mild fever and cough ([@B14]), we recommend that they should be kept under close observation, since damage to the developing nervous system can be devastating. According to the World Health Organization (WHO), recent findings on symptoms in children testing positive for COVID-19 have shown unexplained inflammatory syndrome, mostly in several European and North American countries ([@B95]). However, due to the uncertainties of the definitions of symptoms associated with COVID-19 in children, it is important that more evidence is allowed to emerge before their presenting symptoms are categorized into definite neurological and/or musculoskeletal symptoms ([@B95]).

This review has multiple strengths, such as the estimation of prevalence for both neurological and musculoskeletal manifestations, the inclusion of a large number of studies (*n* = 60) with considerable sample size (*n* = 11, 069), the assessment of methodological quality and the level of evidence, and the use of proportional meta-analyses for the quantitative data. In addition, even though two systematic reviews on the neurological features of COVID-19 have been published previously ([@B96], [@B97]), this review seems to be the only one reporting symptoms such low-back and facial pain. Similarly, the study also has some limitations. One of the limitations is that the reviewed studies could not account for whether or not the neurological and musculoskeletal symptoms of COVID-19 are due to the comorbidities and/or the medicines the patients use for the comorbidities. This is because a number of comorbidities are reported in the studies, and possibly the comorbidities or the drugs the patients take may be responsible for one or more of these neurological or musculoskeletal symptoms. Other limitations are related to the search process, where gray literature databases were not searched and non-English language studies were not included. However, the lists of references of all included studies were screened to include all relevant studies and reduce the risk of publication bias. Furthermore, the heterogeneity between studies was high in most of the meta-analysis results. This may impact negatively on the certainty of the findings.

Conclusions {#s6}
===========

Patients with COVID-19 present with many different symptoms, including those that affect the neurological and musculoskeletal systems. Therefore, delineating the whole spectrum of symptoms of the disease can help with early diagnosis, prevention of the spread of the disease, and its treatment. In addition, it will help with the prevention of complications that may arise in the long term.
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